Last updated on April 20, 2014 at 14:04 EDT

Transposagen Biopharmaceuticals, Inc. announces the availability of XTN(TM) TALENs targeting every gene in the human genome

July 17, 2012

LEXINGTON, Ky., July 17, 2012 /PRNewswire/ — Transposagen announced that XTN(TM) site-specific nucleases targeting each gene in the human genome are now available. Utilizing the FLASH(TM) high-throughput system (FLASH assembly of TALENs for high-throughput genome editing. Nature Biotechnology 30, 460-465 (2012)), Transposagen can produce a site-specific nuclease targeting nearly any gene in any genome with the fastest delivery time in the industry. The XTN(TM) site-specific nucleases, also referred to as TALENs, permit researchers to specifically cut any DNA sequence, allowing for the creation of gene knockouts, knock-ins and single base pair edits. Researchers can now search Transposagen’s GENOME discovery database to choose any target. Transposagen will also perform custom cell line engineering and animal model creation using the XTN(TM) technology.

The XTN(TM) technology can be used in conjunction with Transposagen’s other core technology, piggyBac(TM), as the only system in the world that allows for Footprint-Free(TM) genetic engineering down to a single base pair (Bradley et al. Nature 2011). “Researcher’s now have the ability to change a single base-pair or multiple base pairs in any genome without residual unwanted changes, such as the addition of a marker gene or recombinase site,” said Eric Ostertag, President and CEO of Transposagen. The Footprint-Free(TM) genetic engineering system is expected to have applicability in the generation of cell lines and model organisms for functional genomics and the validation of genome-wide association studies (GWAS).

Transposagen is now offering XTN(TM) site-specific nucleases worldwide. Custom and off-the-shelf XTN(TM) reagents are available through Transposagen (http://www.transposagenbio.com/rats/xtn-tal-nucleases.html) and with the following distributors:

GENTAUR Molecular Products
APRO Life Science Institute Inc. – Japan
MJS Biolynx Inc. – Canada
ITSI-Biosciences Inc.
DPC/LEBANON sarlMiddle East
BioCat GmBh – Germany, Austria & Switzerland

About Transposagen Biopharmaceuticals, Inc.
Transposagen Biopharmaceuticals, Inc., a Lexington, KY-based company, is a worldwide leader in technologies and services for genetic modification. Transposagen is dedicated to providing better disease models through genetic modification. Transposagen specializes in custom and off-the-shelf XTN(TM) site-specific nucleases, animal models, cell lines, stem cells and cutting-edge research tools and technologies to improve drug discovery and development research. These unique technologies and services for genetic modification give customers the ability to create nearly any genetic modification in any genome for both research and protein production purposes.

Media Contact:
Jack Crawford

SOURCE Transposagen Biopharmaceuticals, Inc.

Source: PR Newswire